Results 181 to 190 of about 51,637 (307)

Pain and treatment outcomes after initiating methadone vs buprenorphine among medicare patients with opioid use disorder and comorbid chronic pain: A target trial emulation. [PDF]

PLoS Med
Wei YJ, Winterstein AG, Fillingim RB, Schmidt S, Schmidt S.   +4 more
europepmc   +1 more source

Prenatal Prescription Opioid Analgesic Exposure and Academic Performance in Third Grade Children: A Population‐Based Cohort Study

BJOG: An International Journal of Obstetrics &Gynaecology, Volume 133, Issue 8, Page 1658-1670, July 2026.
ABSTRACT Objective To evaluate the association between prenatal exposure to opioids analgesics and academic performance in third grade children. Design Population‐based cohort study using linked data from New South Wales birth records, medicine dispensing data, and national standardised test results.
Bianca Varney, Helga Zoega, Malcolm B. Gillies, Claudia Bruno, Alys Havard, Antonia Shand, Natasha Nassar, Jonathan Brett   +7 more
wiley   +1 more source

Failed transition to buprenorphine extended-release injection from high-dose methadone. [PDF]

Ment Health Clin
Jhawar A, Menard-Okoroike S.
europepmc   +1 more source

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, Volume 183, Issue 14, Page 3970-3991, July 2026.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology

British Journal of Pharmacology, Volume 183, Issue 14, Page 4022-4047, July 2026.
Theorized mechanism of dopamine homeostasis restoration in the nucleus accumbens core induced by a psychedelic intervention. Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive ...
Lucas Wittenkeller, Gary Gudelsky, T. John Winhusen, Davide Amato   +3 more
wiley   +1 more source

An opioid-withholding human laboratory paradigm during opioid agonist treatment for opioid use disorder and chronic pain: Phase- and dose-dependent effects of cannabidiol. [PDF]

Neuropsychopharmacology
P A Costa G, Sofuoglu M, Compton P, Ranganathan M, Pittman B, De Aquino JP.   +5 more
europepmc   +1 more source

Health, Social and Recidivism Outcomes Among People Who Have Been Incarcerated in New South Wales, Australia: Study Protocol and Cohort Profile for the Prison Outcomes STudy (POST)

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction We have been funded to examine post‐incarceration health and social outcomes for all people incarcerated in New South Wales, Australia, 2000–2022; assess treatment and services for drug dependence and serious mental illness; and project the impact of expanding intervention coverage. We will use a linked cohort, the Prison Outcomes
Louisa Degenhardt, Michael Farrell, Michael Doyle, Jack Stone, Chrianna Bharat, Matt Hickman, Marianne Martinello, Don Weatherburn, Kimberlie Dean, Joe Coyte, Christel Macdonald, Mary Ellen Harrod, Luke Grant, Gloria Larman, Peter Vickerman, Colette McGrath, Peter Thompson, Alison Churchill, Greg Dore, Thomas Santo Jr   +19 more
wiley   +1 more source

Differential Impacts of Methadone and Buprenorphine/Naloxone on Pain‐Related Outcomes Among People With Non‐Heroin Opioid Use Disorder: Secondary Analyses From a Pragmatic Canadian Multisite Trial

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction In addition to their use as opioid agonist therapy (OAT), methadone and buprenorphine/naloxone also have analgesic properties. However, there is limited information on the relative effectiveness of these medications for analgesia in the context of treatment for non‐heroin opioid use disorder (OUD).
Katie Lyman, JinCheol Choi, Didier Jutras‐Aswad, Bernard L. E. Foll, Sukhpreet Klaire, M. Eugenia Socias   +5 more
wiley   +1 more source

Accuracy of Patient‐Reported Exposure to New Psychoactive Substances and Other Illicit Drugs in Australian Emergency Departments: Findings From the Emerging Drugs Network of Australia

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction New psychoactive substances (NPS) present a unique challenge in clinical, public health and drug‐policy contexts. Continued diversity, unknown potency and often unintentional exposure can limit the accuracy of self‐reported data.
Marjan J. Nijmeijer, Jennifer L. Smith, Courtney Weber, Bas W. J. Bens, Daniel M. Fatovich, Shaun L. Greene, Jennifer L. Schumann, Paul Dessauer, Rebekka Syrjanen, Katherine Z. Isoardi, Keith Harris, Sam Alfred, Viet Tran, Ewoud ter Avest   +13 more
wiley   +1 more source

Would we, could we? Measuring attitudinal and capacity barriers to supporting recovery housing residents on medication for opioid use disorder. [PDF]

J Subst Use Addict Treat
Winograd RP, Park B, Ghonasgi R, Paschke M, Mericle AA.   +4 more
europepmc   +1 more source